Exosomes Archives | Page 27 of 27

Evox Therapeutics to Collaborate with Boehringer Ingelheim on Exosome-Mediated Drug Delivery

December 20, 2017 By Cade Hildreth, Founder & President Leave a Comment

Adds to list of pharmaceutical partners collaborating with Evox

OXFORD, England, December 19, 2017–Evox Therapeutics Ltd (‘Evox’ or the ‘Company’), a leading exosome therapeutics company, today announces that it has entered into a research collaboration with Boehringer Ingelheim to investigate exosome-mediated delivery of RNAs with high medical relevance to targets for specific disease areas of focus to Boehringer Ingelheim. The collaboration is part of Boehringer Ingelheim’s Research Beyond Borders (RBB) initiative that explores emerging science and technologies for and beyond its core therapeutic areas to create new opportunities in disease indications of high medical need.
[Read more…]

Exosome Company Codiak BioSciences Closes $76.5 Million in Series C Financing

December 5, 2017 By Cade Hildreth, Founder & President Leave a Comment

CAMBRIDGE, Mass., Nov. 29, 2017 — Codiak BioSciences, Inc., the leading exosome therapeutics company, today announced the closing of a Series C financing round of $76.5 million. In its two years as a company Codiak’s funding totals $168.5 million. Codiak’s initial investors, including ARCH Venture Partners, Flagship Pioneering, Fidelity Management and Research Company, the Alaska Permanent Fund, and Alexandria Venture Investments, participated in the Series C round, and were joined by new investors, including Qatar Investment Authority, Boxer Capital of the Tavistock Group, Sirona Capital, EcoR1 Capital, and Casdin Capital.

[Read more…]

Avalon GloboCare Acquires Leading Beijing Exosome Technology Company

December 3, 2017 By Cade Hildreth, Founder & President Leave a Comment

Avalon Forms Subsidiary U.S. Company, GenExosome Technologies Inc., for the Global Advancement of Exosome Technology for Diagnosis and Treatment of Diseases

FREEHOLD, NJ–(October 30, 2017) – Avalon GloboCare Corp. (OTCQB: AVCO), a leading global developer of cell-based technologies, announced today that its majority-owned subsidiary GenExosome Technologies Inc. (GenExosome) acquired 100% of the outstanding capital stock of Beijing Jieteng (Beijing GenExosome) Biotech Co. Ltd. Concurrently, GenExosome entered into and closed an Asset Purchase Agreement with Dr. Yu Zhou, CEO of GenExosome Beijing, pursuant to which GenExosome acquired all assets, including all intellectual property, patents and patent applications held by Dr. Zhou pertaining to the business of researching, developing and commercializing exosome technologies. Additional details of the transaction are available in the Company’s form 8-K filed with the Securities & Exchange Commission on October 27, 2017, and is available at www.sec.gov.
[Read more…]

WideCells’ CellPlan Insurance is Live – 1st Sales Made to Biovault’s Base of Cord Blood Banks

January 8, 2017 By Cade Hildreth, Founder & President Leave a Comment

World first stem cell insurance plan, CellPlan, secures maiden sales agreement signaling commencement of commercial roll out.

CellPlan Limited (‘CellPlan’), which has developed the world’s first stem cell healthcare insurance plan and medical concierge service, has cemented its agreement with Biovault Technical Ltd (‘Biovault’), the UK’s largest private human tissue storage facility via a definitive agreement. CellPlan is part of London-listedWideCells Group plc, the healthcare services company focused on providing end-to-end stem cell services. [Read more…]

Global Cooperation – MD Anderson and NIH to Fund Clinical Trial Combining Mesoblast Technologies

December 8, 2016 By Cade Hildreth, Founder & President Leave a Comment

MD Anderson Cancer Center and National Institutes of Health to Fund Trial Combining 2 Proprietary Mesoblast Technologies for Rapid Engraftment of Stem Cell Transplants in Cancer Patients

New York, USA; and Melbourne, Australia; December 6, 2016: Mesoblast Limited (ASX:MSB; Nasdaq:MESO) today announced that MD Anderson Cancer Center (MDACC) in Texas and the United States National Institutes of Health (NIH) will fund a clinical trial combining Mesoblast’s two synergistic proprietary technologies, Mesenchymal Precursor Cell (MPC)-based expansion and ex-vivo fucosylation of hematopoietic stem cells (HSCs) for cord blood transplantation in cancer patients. The trial will provide clinical data on whether the combination of these two technologies synergistically facilitates more rapid cord blood HSC engraftment for bone marrow transplant patients than can be achieved by either technology alone.

The number of allogeneic bone marrow transplants performed globally each year could be substantially increased beyond the current 30,000, for cancer and non-cancer indications, if safe and effective alternative sources of allogeneic HSCs are available, such as cord blood, for patients who cannot find a matched donor. Unfortunately, cord blood transplants are associated with prolonged engraftment times due to insufficient numbers and inadequate homing capacity of cord blood HSCs, adversely impacting their clinical outcomes. [Read more…]